316 related articles for article (PubMed ID: 24625262)
1. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.
Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z
Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262
[TBL] [Abstract][Full Text] [Related]
2. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
3. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanoparticles loaded with 10-hydroxycamptothecin-phospholipid complex developed for the treatment of hepatoma in clinical application.
Wei W; Shi SJ; Liu J; Sun X; Ren K; Zhao D; Zhang XN; Zhang ZR; Gong T
J Drug Target; 2010 Aug; 18(7):557-66. PubMed ID: 20131981
[TBL] [Abstract][Full Text] [Related]
5. Solid lipid nanoparticles containing 7-ethyl-10-hydroxycamptothecin (SN38): Preparation, characterization, in vitro, and in vivo evaluations.
Mosallaei N; Mahmoudi A; Ghandehari H; Yellepeddi VK; Jaafari MR; Malaekeh-Nikouei B
Eur J Pharm Biopharm; 2016 Jul; 104():42-50. PubMed ID: 27108266
[TBL] [Abstract][Full Text] [Related]
6. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
[TBL] [Abstract][Full Text] [Related]
7. SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study.
Fang YP; Chuang CH; Wu YJ; Lin HC; Lu YC
Int J Nanomedicine; 2018; 13():2789-2802. PubMed ID: 29785106
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
[TBL] [Abstract][Full Text] [Related]
9. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
10. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
[TBL] [Abstract][Full Text] [Related]
11. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.
Pal A; Khan S; Wang YF; Kamath N; Sarkar AK; Ahmad A; Sheikh S; Ali S; Carbonaro D; Zhang A; Ahmad I
Anticancer Res; 2005; 25(1A):331-41. PubMed ID: 15816556
[TBL] [Abstract][Full Text] [Related]
12. Intracellular target delivery of 10-hydroxycamptothecin with solid lipid nanoparticles against multidrug resistance.
Liu M; Chen D; Wang C; Chen X; Wen Z; Cao Y; He H
J Drug Target; 2015; 23(9):800-5. PubMed ID: 25766079
[TBL] [Abstract][Full Text] [Related]
13. BR2 and CyLoP1 enhance in-vivo SN38 delivery using pegylated PAMAM dendrimers.
Mahmoudi A; Jaafari MR; Ramezanian N; Gholami L; Malaekeh-Nikouei B
Int J Pharm; 2019 Jun; 564():77-89. PubMed ID: 30991135
[TBL] [Abstract][Full Text] [Related]
14. Polypeptide-based Micelles for Delivery of Irinotecan: Physicochemical and In vivo Characterization.
Ramasamy T; Choi JY; Cho HJ; Umadevi SK; Shin BS; Choi HG; Yong CS; Kim JO
Pharm Res; 2015 Jun; 32(6):1947-56. PubMed ID: 25471199
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
[TBL] [Abstract][Full Text] [Related]
16. [Irinotecan pharmacokinetics].
Chabot GG; Robert J; Lokiec F; Canal P
Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
[TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
Lei S; Chien PY; Sheikh S; Zhang A; Ali S; Ahmad I
Anticancer Drugs; 2004 Sep; 15(8):773-8. PubMed ID: 15494639
[TBL] [Abstract][Full Text] [Related]
18. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M
Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes.
Chen M; Li W; Zhang X; Dong Y; Hua Y; Zhang H; Gao J; Zhao L; Li Y; Zheng A
Int J Nanomedicine; 2017; 12():5487-5500. PubMed ID: 28814865
[TBL] [Abstract][Full Text] [Related]
20. MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery.
Sayari E; Dinarvand M; Amini M; Azhdarzadeh M; Mollarazi E; Ghasemi Z; Atyabi F
Int J Pharm; 2014 Oct; 473(1-2):304-15. PubMed ID: 24905777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
